RBC Capital analyst Mike Dahl maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $27 to $28.
RBC Capital Maintains Outperform on Core & Main, Raises Price Target to $28
RBC Capital analyst Mike Dahl maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $27 to $28.
Related Posts
ENHERTU Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers
Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer
ENHERTU has now been granted seven
Elon Musk Suggested This GOP Presidential Candidate Post Podcasts ‘Directly’ On X…. And He Complied
Elon Musk encouraged GOP presidential candidate Vivek Ramaswamy to post his podcasts on Twitter (now rebranded as X), leading to his swift compliance.
Marijuana Giant Trulieve Boosts Cash Position With $25M Loan, Opens Cannabis Stores In Florida
Florida-based medical cannabis firm Trulieve Cannabis has secured $25m of gross proceeds from a five-year loan. The company will pay interest of 8.31% until the loan matures. The deal, arranged with First Federal bank, gives Trulieve greater flexibility, according to CEO Kim Rivers. She said the loan would boost the company's cash position as it gears up for growth opportunities. The company revealed the financing at the same time as the opening of two new medical dispensaries in Florida: one in Crawfordville and another in Crestview. Trulieve will stock products from in-house brands Modern Flower, Muse, Trekkers and many others. The dispensaries will also carry product from partner brands, including Alien Labs.